Nothing Special   »   [go: up one dir, main page]

MA55504A - Anticorps dirigés contre le liraglutide et leur utilisation - Google Patents

Anticorps dirigés contre le liraglutide et leur utilisation

Info

Publication number
MA55504A
MA55504A MA055504A MA55504A MA55504A MA 55504 A MA55504 A MA 55504A MA 055504 A MA055504 A MA 055504A MA 55504 A MA55504 A MA 55504A MA 55504 A MA55504 A MA 55504A
Authority
MA
Morocco
Prior art keywords
liraglutide
antibodies against
antibodies
against liraglutide
Prior art date
Application number
MA055504A
Other languages
English (en)
Inventor
Arne Staby
Samuel D Stimple
Peter M Tessier
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA55504A publication Critical patent/MA55504A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
MA055504A 2019-04-01 2020-03-31 Anticorps dirigés contre le liraglutide et leur utilisation MA55504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962827444P 2019-04-01 2019-04-01

Publications (1)

Publication Number Publication Date
MA55504A true MA55504A (fr) 2022-02-09

Family

ID=70154403

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055504A MA55504A (fr) 2019-04-01 2020-03-31 Anticorps dirigés contre le liraglutide et leur utilisation

Country Status (6)

Country Link
US (2) US11208477B2 (fr)
EP (1) EP3947451A1 (fr)
JP (1) JP2022527812A (fr)
CN (1) CN113677702A (fr)
MA (1) MA55504A (fr)
WO (1) WO2020201280A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240034778A1 (en) * 2020-12-22 2024-02-01 The Regents Of The University Of Michigan Amyloid-specific antibodies and uses thereof
CN116425858B (zh) * 2023-03-01 2024-04-19 浙江大学 一种荧光修饰的司美格鲁肽衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620850A (en) 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
AU5685296A (en) 1995-05-17 1996-11-29 Novo Nordisk A/S Immunoassay for glucagon like protein 1 (glp-1) in plasma
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
EP0979102A4 (fr) 1997-04-30 2005-11-23 Enzon Inc Polypeptides a chaine unique modifies par oxyde de polyalkylene
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
DE602004031455D1 (de) * 2003-12-09 2011-03-31 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1-agonisten
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1968645A4 (fr) 2005-12-22 2009-11-04 Centocor Ortho Biotech Inc Corps mimetiques humains glp-1 et compositions pour traiter l'obesite et les troubles associes, procedes et utilisations
WO2009143014A1 (fr) 2008-05-23 2009-11-26 Amylin Pharmaceuticals, Inc. Biodosages de l'agoniste du récepteur du glp-1
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
AU2014250730B2 (en) * 2009-12-07 2016-10-13 Amgen Inc. Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof
AU2012207068A1 (en) 2011-01-21 2013-09-12 Ir2Dx, Inc. Biomarkers for rapid determination of drug efficacy
CA2878640C (fr) * 2012-07-13 2023-10-24 Zymeworks Inc. Conception d'echafaudages heteromultimeres et produits de recombinaison
WO2014056199A1 (fr) 2012-10-12 2014-04-17 清华大学 Procédés de production et de purification d'un polypeptide
US20160296632A1 (en) 2013-11-13 2016-10-13 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
AR098615A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103884846B (zh) 2014-03-06 2016-06-08 杭州九源基因工程有限公司 一种利拉鲁肽生物学活性的检测方法
GR20140100479A (el) * 2014-09-23 2016-05-05 Novetide, Ltd., Συνθεση λιραγλουτιδης
CN104267194B (zh) 2014-09-23 2016-01-13 上海市东方医院 人胰高血糖素样肽-1、抗体及其试剂盒
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos

Also Published As

Publication number Publication date
JP2022527812A (ja) 2022-06-06
US20220064283A1 (en) 2022-03-03
US11208477B2 (en) 2021-12-28
EP3947451A1 (fr) 2022-02-09
WO2020201280A1 (fr) 2020-10-08
CN113677702A (zh) 2021-11-19
US20200308274A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
UA42761S (uk) Футляр для зберігання та заряджання навушників
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA53434A (fr) Anticorps anti-tigit
IL277447A (en) Cell-adapted exosomes and their uses
IL279458A (en) Neoantigens and their uses
MA49823A (fr) Anticorps dirigés contre pd-l1
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
MA41316A (fr) Gènes de détermination du sexe et leur utilisation en reproduction
MA52542A (fr) Thérapie cellulaire adoptive
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
UA41767S (uk) Ємність
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
IL284561A (en) Neoantigens of the prostate and their uses
MA52366A (fr) Anticorps anti-tl1a optimisés
MA49250A (fr) Nouveaux anticorps anti-cd3
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA44067A (fr) Anticorps dirigés contre la quétiapine et utilisation associée
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
IL287690A (en) Antibodies against hvem and their use